CTLA4 and non-small cell lung carcinoma: We tested the concurrent anti-PD-1/CTLA-4/Ly6C therapy in multiple other KP NSCLC animal models and consistently observed that the resistance to anti-PD-1/CTLA-4 treatment was reversed by anti-Ly6C antibody treatment in 393P, 344P, and 412P KP syngeneic models (Figures 2F-H, S2A-D).